季度财报
Karyopharm(KPTI)05-09 04:15
$Karyopharm(KPTI)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-055672 Act: 34 Size: 7 MB 网页链接
简介:Karyopharm Therapeutics Inc.是一家专注于研发新式一期核运输癌症治疗方法的临床型制药公司。公司的科学专业知识集中于对细胞核和细胞质之间核运输的研究。公司已经研发出全资拥有的,新奇的,小分子式的核运输选择性抑制剂,以及抑制核运输的正弦蛋白质XPO1。公司最重要的候选药物Selinexor (KPT-330),属于尚在评估中的XPO1抑制剂,该抑制剂尚属于并联标记第一期临在医疗患者中临床试验的阶段,这些试验对象主要包括预防复发或血液和固体的恶性肿瘤。Karyopharm Therapeutics Inc.于2008年12月22日在特拉华州作为一家临床阶段制药公司成立,并在马萨诸塞州的纳迪克拥有了主要营业地点。
今开:0.8218 | 昨收:0.8155 |
最高:0.843 | 最低:0.785 |
涨停价: | 跌停价: |
总市值:99692586 |
Karyopharm(KPTI)05-09 04:15
$Karyopharm(KPTI)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-055672 Act: 34 Size: 7 MB 网页链接
Karyopharm(KPTI)05-31 04:15
$Karyopharm(KPTI)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-24-150328 Act: 33 Size: 71 KB 网页链接
Karyopharm(KPTI)05-31 04:55
$Karyopharm(KPTI)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001193125-24-150438 Act: 33 Size: 312 KB 网页链接
Karyopharm(KPTI)06-05 06:55
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-068969 Size: 15 KB 网页链接
Karyopharm(KPTI)06-20 20:05
$Karyopharm(KPTI)$ SC TO-I Tender offer statement by Issuer Accession Number: 0001193125-24-164000 Act: 34 Size: 7 MB 网页链接
Karyopharm(KPTI)04-19 19:45
$Karyopharm(KPTI)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-24-045718 Act: 34 Size: 1 MB 网页链接
Karyopharm(KPTI)05-15 04:15
$Karyopharm(KPTI)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-24-138211 Act: 34 Size: 4 MB 网页链接
Karyopharm(KPTI)06-10 18:05
$Karyopharm(KPTI)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001788 Act: 33 Size: 1 KB 网页链接
Karyopharm(KPTI)04-06 05:25
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-042350 Size: 4 KB 网页链接
Karyopharm(KPTI)05-08 05:05
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-054686 Size: 4 KB 网页链接
酒鬼爱花生03-11 12:47
$Karyopharm(KPTI)$ 和德琪医药市值相当,因塞里尼所结缘的两家公司查看全文
jesseWarrenSoros02-06 23:10
LAES16802-06 01:29
$Karyopharm(KPTI)$ 逆市飘扬,传被一家大型公司收购。查看全文
LAES16802-03 04:01
LAES16802-01 08:54
$Karyopharm(KPTI)$ 尾盘1️⃣笔50多万砸给了自己人,盘后又收回。看来要启动了查看全文
LAES16802-01 00:32
LAES16801-30 02:56
药智网2023-08-24 15:20
来源:药智网公众号
图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm(KPTI)$ SC TO-I Tender offer statement by Issuer Accession Number: 0001193125-24-164000 Act: 34 Size: 7 MB 网页链接
$Karyopharm(KPTI)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001788 Act: 33 Size: 1 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-070991 Size: 15 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069856 Size: 4 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069860 Size: 4 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-068969 Size: 15 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, items 5.02, 5.07, and 9.01 Accession Number: 0001193125-24-151049 Act: 34 Size: 168 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-066781 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-066782 Size: 5 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-066785 Size: 5 KB 网页链接